How a licensing deal could net Babraham's Abzena $35m

« Back to Industry News

03/01/2017

Abzena has received an early Christmas present with the news that it could be in line for $35m after signing a licensing agreement.

The Babraham firm has agreed a deal with Trieza Therapeutics, a biotech start-up based in the Boston version of Cambridge that specialises in the discovery and development of immunomodulatory oncolytic viruses.

Abzena, which provides services and technologies to enable the development and manufacture of biopharmaceutical products, has granted Trieza an exclusive worldwide, royalty bearing, sub-licensable licence to an undisclosed antibody sequence, which was created using the group’s Composite Human Antibody technology. This will be explored in conjunction with Trieza’s viral vector technology to develop novel therapies in oncology.

Dr John Burt, Abzena’s CEO, said: “This new licence deal with Trieza provides the opportunity for Abzena to benefit from the commercialisation of one of the assets originally developed by the group to exemplify its proprietary antibody humanization and deimmunisation technology. Our Abzena inside portfolio already has eleven products in the clinic that have benefitted from this technology.”

Under the terms of the deal, Abzena could receive up to $35m in development and commercial milestone payments, as well as royalties on the sale of licensed products containing the Abzena sequence.

Dr Dan Hicklin, Trieza Therapeutics’ CEO, said: “We are pleased to enter this relationship with Abzena. Access to Abzena’s technology will accelerate the development of Trieza’s portfolio of immunotherapeutic oncolytic virus product candidates.”

It’s been a good year for Abzena, which last month announced that revenue was up 157% in 2016. At the time, Dr Burt revealed to the News that the comapny was trying to make further in-roads into the American biopharmaceutical market.


Click here to view the related article.

« Back to Industry News